DA-9601 for erosive gastritis: Results of a double-blind placebo-controlled phase III clinical trial

doi:10.3748/wjg.v10.i16.2379

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4894)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

368

HTML

4148

Figures (1-5)

199

Tables (1-5)

179

Sum=4894

Aug 15, 2004 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (39)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Aug 15, 2004; 10(16): 2379-2382
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2379

Full Size Figure Download Figure

Figure 1 Estimated cure rates of erosive gastritis by intention-to-treat (ITT) analysis among patients treated with DA-9601 (180 mg or 360 mg, t. i.d.) or cetraxate (600 mg, t.i.d.) for 2 wk. ^aP < 0.05 vs 600 mg of cetraxate.

Citation: Seol SY, Kim MH, Ryu JS, Choi MG, Shin DW, Ahn BO. DA-9601 for erosive gastritis: Results of a double-blind placebo-controlled phase III clinical trial. World J Gastroenterol 2004; 10(16): 2379-2382
URL: https://www.wjgnet.com/1007-9327/full/v10/i16/2379.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i16.2379